These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28055196)

  • 21. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
    Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
    Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
    Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
    Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[
    Ritawidya R; Ludwig FA; Briel D; Brust P; Scheunemann M
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31370274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
    Gu G; Scott T; Yan Y; Warren N; Zhang A; Tabatabaei A; Xu H; Aertgeerts K; Gomez L; Morse A; Li YW; Breitenbucher JG; Massari E; Vivian J; Danks A
    J Pharmacol Exp Ther; 2019 Sep; 370(3):399-407. PubMed ID: 31253692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.
    Huang Y; Wu XN; Zhou Q; Wu Y; Zheng D; Li Z; Guo L; Luo HB
    J Med Chem; 2020 Dec; 63(24):15852-15863. PubMed ID: 33291877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
    Chen Z; Tian G; Wang Z; Jiang H; Shen J; Zhu W
    J Chem Inf Model; 2010 Apr; 50(4):615-25. PubMed ID: 20353193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer's Disease.
    Zhou Y; Li J; Yuan H; Su R; Huang Y; Huang Y; Li Z; Wu Y; Luo H; Zhang C; Huang L
    Molecules; 2021 May; 26(10):. PubMed ID: 34069639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.
    Fan HT; Guo JF; Zhang YX; Gu YX; Ning ZQ; Qiao YJ; Wang X
    Mol Med Rep; 2018 Jan; 17(1):388-393. PubMed ID: 29115449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
    Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
    Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A.
    Módis K; Panopoulos P; Coletta C; Papapetropoulos A; Szabo C
    Biochem Pharmacol; 2013 Nov; 86(9):1311-9. PubMed ID: 24012591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Inhibition Modality for Phosphodiesterase 2A.
    Nakashima K; Matsui H
    SLAS Discov; 2020 Jun; 25(5):498-505. PubMed ID: 32343157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.
    Yu YF; Zhang C; Huang YY; Zhang S; Zhou Q; Li X; Lai Z; Li Z; Gao Y; Wu Y; Guo L; Wu D; Luo HB
    ACS Chem Neurosci; 2020 Apr; 11(7):1058-1071. PubMed ID: 32105440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing of potential inhibitors against Staphylococcus aureus sortase A: Combined analogue and structure based approach with in vitro validation.
    Raj KK; Ganesh Kumar V; Leela Madhuri C; Mathi P; Durga Lakshmi R; Ravi M; Sri Ramudu B; Venkata Rao SV; Ramachandran D
    J Mol Graph Model; 2015 Jul; 60():89-97. PubMed ID: 26119984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
    Zhu J; Yang Q; Dai D; Huang Q
    J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors.
    Niinivehmas SP; Virtanen SI; Lehtonen JV; Postila PA; Pentikäinen OT
    J Chem Inf Model; 2011 Jun; 51(6):1353-63. PubMed ID: 21591817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.